Please assess the completion status of the following clinical trial:

Trial Title: Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Female or male subjects, at least 27 years old.~2. Confirmed diagnosis of intra-anal HSIL at least 3 months prior to screening and confirmed by histopathology (with p16 positive staining)~3. Intra-anal HSIL are visible and evaluable by HRA at the time of screening, and no lesion(s) is suspicious for invasive cancer.~4. For HIV-positive subjects, CD4 count must be at least 200/mm3 with undetectable (\<50 copies/mL) viral load within the 3 months prior to enrollment. Subjects must be on a stable regimen of antiretroviral drugs for the 3 months prior to enrollment.~Exclusion Criteria:~1. Women who are pregnant, plan to become pregnant in the next 3 months, or lactating females.~2. Received topical treatment or ablative procedures for aHSIL in the 6 months prior to enrolment.~3. History of cancer involving the anogenital region, or history of other cancers that have not been fully resolved and free of symptoms in the past 5 years~4. History of genital herpes with \> 3 outbreaks per year.~5. Plan to have excision or ablation of the lesion(s) within 3 months of enrolment.

- Gender: ALL
- Minimum Age: 27 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose 1 - Multiple Ascending Dose(MAD) (Type: EXPERIMENTAL): Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
- Dose 2 - Multiple Ascending Dose(MAD) (Type: EXPERIMENTAL): Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
- Dose 3 - Multiple Ascending Dose(MAD) (Type: EXPERIMENTAL): Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic

Based on this trial design, predict the completion outcome and termination type (if applicable).